A new extra long acting depot preparation of the LHRH analogue Zoladex®. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function

“…After that, the castrated patients had a further decline, unlike those receiving bicalutamide. This is consistent with the change in testosterone after medical castration (which was used in 86% of the castration group); the concentrations, after an initial increase (flare), decreased to within the castrate range within 21 days [67]. A dramatic and sustained fall in sexual interest follows the reduction in testosterone concentrations.…”

Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer

“…Thus, it seems to be very important to develop a longer-acting goserelin formulation since such a formulation requires fewer clinic visits and could potentially increase convenience for the patient. In patients with prostate cancer, a long-acting goserelin formulation given once every 3 months (goserelin 10.8 mg) was shown to be equivalent to the 3.6 mg depot in terms of tolerability and pharmacodynamics [9,14], and gained Food and Drug Administration approval for the treatment of prostate cancer in 1996 following Phase III trials which demonstrated non-inferiority between the two dose regimens [15,16]. However, goserelin 10.8 mg is not currently indicated for use in breast cancer.…”

Suppression of puberty with long‐acting goserelin (Zoladex‐LA): effect on gonadotrophin response to GnRH in the first treatment cycle

“…Similar biochemical analysis has previously been carried out on males with advanced prostate cancer in which Zoladex‐LA is routinely used as therapy. This has focused mainly on testosterone suppression and has shown that this is suppressed to surgically castrate levels within 3–4 weeks and remains suppressed for 12–14 weeks after the first injection (Dijkman et al ., 1990, 1995; Fernandez et al ., 1996; Sarosdy et al ., 1999). Although LH was also shown to be initially suppressed in a phase II clinical trial and graphically appears to remain so over 12 weeks, no comments are made regarding the occurrence of any statistical rise towards the end of the treatment cycle (Dijkman et al ., 1990).…”

“…However, the biochemical efficacy of longer‐acting preparations in suppressing gonadotrophins has not yet been addressed in children with precocious or early puberty. Studies in adult males with advanced prostatic cancer have shown that testosterone levels are suppressed to surgically castrate levels for up to 14 weeks (Dijkman et al ., 1990, 1995; Fernandez et al ., 1996; Sarosdy et al ., 1999). Clinical and biochemical efficacy was also found to be comparable between the 3·6 mg and 10·8 mg preparations (Dijkman et al ., 1995; Debruyne et al ., 1996; Fernandez et al ., 1996).…”